IDH2 and acute myeloid leukemia: Other variables, including gender, treatment type (AZA vs. DEC), AP, molecular mutations (NPM1, FLT3 ITD, IDH1, IDH2), cytogenetic risk, AML-CI, and complex karyotype, did not show statistically significant associations with treatment response (Table 1).